A Phase I Study of the Anti-Breast Cancer Immunotoxin 260F9 Mab-rRA Given by Intravenous Continuous Infusion
Immunotoxins(IT) are biologically derived compounds that are under development as anti-neoplastic agents(1`. An immunotoxin consists of a carrier protein that guides a covalently linked toxin to a tumor cell. Monoclonal antibodies which have specificity for tumor cell. Monoclonal antibodies serve as carrier molecules. Plant or bacteria derived toxins such as ricin, pseudomonas exotoxin, and diphtheria toxin are commonly used cellular poisons(2).
KeywordsChronic Lymphocytic Leukemia Inhibit Protein Synthesis Diphtheria Toxin Chest Wall Tumor Refractory Chronic Lymphocytic Leukemia
Unable to display preview. Download preview PDF.
- 6.Data on file at the Cetus Corporation.Google Scholar
- 7.Hertler A, Schlossman D, Borowitz M, Blythnman H, Caselas P, Frankel A. Anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.Inter. J. of Cancer 43: 215–219.Google Scholar
- 9.Spitler L, del Rio M, Khentigan A, Wedel N, Brophy N, Miller L, Harkonen W, Rosendorf L, Lee H, Mischak R, Kawahata R, Stoudemire J, Fradkin L, Bautista E, Scannon P. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibodyricin A chain immunotoxin.Cancer Res. 47: 1717–1723 1987.PubMedGoogle Scholar
- 10.Hertler A, Schlossman D, Borowitz M, Laurent G, Jansen F, Schmidt C, Frankel A. A phase I study of T101 ricin A chain immunotoxin in refractory chronic lymphocytic leukemia J. of Biological Response Modifiers 7: 97–113 1988.Google Scholar